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1. Introduction 
It is a fact we are all too well aware of. The world, as we know it, continues to grow fat. The 
popular press has done an excellent job of educating the lay person about the link between 
obesity and heart disease, hypertension, etc. However, despite scientific evidence to the 
contrary, the effect of obesity on the kidneys’ function is less well-known. Kidney disease 
from obesity can progress to End Stage Renal Disease (ESRD), which mandates the use of 
dialysis to keep the patient alive. It is hence a huge risk factor for morbidity and mortality. 
Last, but not the least, it puts a tremendous economic and social strain on the healthcare 
resources of nations around the world.   
2. The alarming statistics 
The World Health Organization (WHO) considers obesity an international epidemic, stating 
in 1997 that “obesity’s impact is so diverse and extreme that it should now be regarded as 
one of the greatest neglected public health problems of our time with an impact on health 
which may well prove to be as great as that of smoking.” A quick look at the WHO’s 
statistics paints a scary picture of what we are up against. It is hard to imagine that in 2008 
almost one-quarter of humanity, or 1.5 billion people, were reported to be overweight (a 
body mass index greater than or equal to 25). Of these, over 200 million men and 300 million 
women were obese (body mass index greater than or equal to 30). Obesity, in combination 
with diabetes, is the largest epidemic the world has ever faced. It is also the fifth leading 
cause of deaths worldwide, killing 2.8 million people every year.  The prevalence of obesity 
currently ranges from less than 5% in rural China, Japan and some African countries, to 
levels as high as 75% of the adult population in urban Samoa. 68% of U.S. adults are either 
overweight or obese. With this enormous health burden worldwide, the deleterious effects 
of obesity on kidney function are being increasingly recognized.  
2.1 Obesity and kidney disease: The weight of the evidence 
There now is a well established risk between obesity and the development of kidney 
disease. The Framingham Offspring data reported obesity as a major risk factor for the 
development of kidney disease. This was a large study that followed 1223 men and 1362 
women (who were initially free of preexisting kidney disease) for a mean period of 18.5 
years. At the end of this follow up period, 244 participants (9.4 percent) had developed 
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kidney disease (defined as estimated glomerular filtration rate (GFR) of less than 64 and 59 
mL/min per 1.73 m2 for men and women, respectively). The researchers also reported a 
23% increase in the odds of development of kidney disease for each standard deviation 
increase in the Body Mass Index (BMI). This risk was present even after adjustment for age, 
sex, smoking, diabetes, and baseline glomerular filtration rate (GFR). Another study by Hsu 
et al showed that there is a greater relative risk of development of end-stage renal disease 
(ESRD) necessitating dialysis, with each gradient increase in BMI. Higher BMI was a risk 
factor for ESRD in multivariable models that adjusted for age, sex, race, education level, 
smoking status, history of myocardial infarction, serum cholesterol level, urinalysis 
proteinuria, urinalysis hematuria, and serum creatinine level. Compared with persons who 
had normal weight (BMI, 18.5 to 24.9 kg/m2), the adjusted relative risk for ESRD was 1.87 
(95% CI, 1.64 to 2.14) for those who were overweight (BMI, 25.0 to 29.9 kg/m2), 3.57 (CI, 3.05 
to 4.18) for those with class I obesity (BMI, 30.0 to 34.9 kg/m2), 6.12 (CI, 4.97 to 7.54) for 
those with class II obesity (BMI, 35.0 to 39.9 kg/m2), and 7.07 (CI, 5.37 to 9.31) for those with 
extreme obesity (BMI > or = 40 kg/m2). Higher baseline BMI remained an independent 
predictor for ESRD after additional adjustments for baseline blood pressure level and 
presence or absence of diabetes mellitus. 
Similarly, a recent large cohort study of 177570 individuals found obesity to be one of the 
most potent risk factors for the development of ESRD.  
3. How obesity causes kidney disease 
Obesity is associated with multiple other conditions that are known to cause compromised 
renal function, including hypertension, diabetes, hyperuricemia, and the metabolic 
syndrome that can independently have a detrimental effect on renal function. However, as 
we can gauge from the evidence quoted in the above section, obesity has been found to 
cause kidney disease and ESRD even after adjustment for these factors. Hence, the 
pathogenesis of obesity related kidney disease can be sub-classified in to direct and indirect 
effects. 
3.1 Direct effects of obesity on kidney function  
Data from the Framingham Offspring study, the Hypertension Detection and Follow-Up 
Program, and the Multiphasic Health Testing Services Program suggest that obesity may be 
independently associated with the risk of developing chronic kidney disease. Obesity seems to 
cause a change in the renal hemodynamics that promotes progressive kidney disease. These 
changes begin early in the course of obesity, even before overt renal manifestations of obesity 
are clinically apparent. This was shown in a landmark study from a center conducting kidney 
biopsies on obese patients who presented for weight loss/bariatric surgery in Spain. The 
investigators studied the glomerular architecture in renal biopsies of 95 patients undergoing 
bariatric surgery for extreme obesity but whose renal function was clinically normal. These 
subjects had no known prior history of any kidney disease. These patients were then 
compared with a control group of 40 patients undergoing nephrectomy or donating a kidney, 
and having protocol biopsies. This second control group had patients who had normal weight 
and renal function, and were non-diabetic and non-hypertensive. Logistic regression models 
were then applied to determine associations between the clinical and biochemical variables 
and glomerular lesions. Focal and segmental glomerulosclerosis (FSGS) was present in only 
five extremely obese patients but absent in controls. Increased mesangial matrix, podocyte 
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hypertrophy, mesangial cell proliferation, and glomerulomegaly were more frequent in the 
obese cohort than in the control group. Body mass index was found to be a significant 
independent risk factor associated with glomerular lesions in all 135 patients and in the 95 
extremely obese patients. This was hence an elegant demonstration of the fact that even in 
patients with no overt clinical renal symptoms, there were a variety of glomerular 
abnormalities that correlated with body mass, even after adjustment for other factors like high 
blood pressure, diabetes, metabolic syndrome, and sleep apnea. 
3.1.1 The role of adipokines 
One of the keys to unravel obesity’s effect on the kidneys is understanding the concept of 
body-fat as an independent endocrine organ, rather than simply a passive storage depot for 
triglycerides. The overarching factor in this is the dysregulated production of bioactive 
substances called “adipokines” by adipose cells that cause systemic effects, and directly 
influence insulin sensitivity and vascular injury.  
Adipokines, and other neuro-humoral factors, have already been well studied in the 
pathogenesis of obesity. Serum levels of adipokines like leptin correlate with the total body 
fat content. Hence, the levels tend to be higher in the obese. In normal-weight subjects, food 
intake is reduced by systemic leptin administration, but the response to leptin decreases as 
the subjects become obese. This leads to a vicious circle of hyperphagia and obesity. Another 
interesting hormone that plays a role in the pathogenesis of obesity is ghrelin, a peptide 
produced by the stomach and duodenum. This peptide stimulates growth hormone 
secretion, and increases food intake in rodents and humans. Serum concentrations are 
suppressed by food ingestion in normal-weight subjects. However, this suppression is 
impaired in the obese, leading to increased food intake.  
Not surprisingly, dysregulated adipokine production also leads to hemodynamic and 
structural changes in the kidney, and has been shown to play an important 
pathophysiologic role in obesity related kidney disease. These adipokines include cytokines 
like leptin, adiponectin, interleukin-6, tumor necrosis factor-alpha, resistin, and 
angiotensinogen.   Whereas some of these adipokines act in an autocrine or paracrine 
manner, others act as signaling molecules in remote tissues like liver, skeletal muscle, and 
endothelium.  These cytokines then induce a pro-inflammatory state causing glomerular 
capillary hypertension, and fibrosis in the renal parenchyma. Of these adipokines, one of the 
best understood roles is that of angiotensinogen. Angiotensinogen is an α-2-globulin that is 
produced constitutively, mainly by the liver. However, plasma levels of angiotensin are also 
positively correlated with body fat mass, indicating increased production of this molecule 
from adipocytes. In fact, all other components of the renin-angiotensin system (RAS), 
including renin, angiotensin converting enzyme, angiotensin II, and AT-1 and AT-2 
receptors, are expressed as well as secreted from adipocytes. Increased angiotensinogen 
kick-starts the RAS, and in turn increases the downstream effects of this system, namely, 
fluid retention and increased vascular tone.  Elevated levels of angiotensinogen and 
angiotensin II then lead to efferent arteriolar constriction in the glomerulus. This increases 
the intraglomerular pressure, leading to a rise in the GFR. From an evolutionary standpoint, 
acutely this adaptation served to preserve GFR and prevent low blood pressure in the face 
of volume depletion. However, over the long term, this effect becomes maladaptive. Raised 
intraglomerular pressure causes injury to the glomerulus and subsequent hyperfiltration. 
Eventually, the kidneys start to spill protein in to the urine and begin to undergo permanent 
irreversible fibrosis.  
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The relation between RAS and body fat is actually a two-way street. In 1998, Karlsson et al 
demonstrated that angiotensin-II stimulated preadipocyte differentiation, and hence 
stimulates adipogenesis. Thus, the RAS itself may also be involved in regulation of body 
weight and development of obesity. RAS has also been postulated to play an important 
role in the development of the cardiomyopathy commonly occurring in obesity. The 
discovery of these mechanisms has had immense clinical implications. Drugs that block 
the RAS now form the mainstay of treatment to decrease glomerular hyperfiltration and 
proteinuria, and have found clinical applications in the prevention and treatment of 
endothelial dysfunction, obesity-related glomerulopathy, diabetic nephropathy, 
cardiomyopathy etc. Clinical trials of strategies to block the RAS after coronary 
angioplasty have demonstrated significant decreases in inflammatory markers of systemic 
inflammation, including IL-6, CRP, and TNF-alpha in response to inhibition of the renin-
angiotensin axis.     
3.1.2 Other hemodynamic and structural effects  
The first large renal-biopsy based clinico-pathologic study on obesity-related kidney disease 
studied the incidence and structural changes seen in obesity-related glomerulopathy (ORG). 
This study reviewed 6818 kidney biopsies and reported the presence of structural changes 
like hyperplasia of the juxta-glomerular apparatus, consistent presence of glomerulomegaly 
and foot process fusion in patients who were diagnosed to have ORG. Another histologic 
feature noted in some ORG patients was the presence of focal changes in the form of mild 
focal mesangial sclerosis or mild focal thickening of glomerular/tubular basement 
membranes. These changes were not very dissimilar to changes that are more often 
associated with the presence of diabetic nephropathy. 
Obese patients have also been shown to have elevations in both renal plasma flow  
and GFR. A study investigated differential solute clearances to characterize glomerular 
function in 12 nondiabetic subjects with severe obesity (body mass index >38). Glomerular 
filtration rate (GFR) and renal plasma flow (RPF) was found to exceed the control  
value by 51 and 31%, respectively. Consequently, the filtration fraction was increased  
as well. The augmented RPF suggests a state of renal vasodilatation involving mainly  
the afferent arteriole. The analysis suggests that the high GFR in very obese subjects  
may be the result of an increase in transcapillary hydraulic pressure difference. An 
abnormal transmission of increased arterial pressure to the glomerular capillaries through 
a dilated afferent arteriole could account for the augmentation in this transcapillary 
pressure. 
3.2 Indirect effects 
Certain co-morbid conditions that come as a “package deal” in patients afflicted with 
obesity serve as indirect agents of destruction of renal function. The strong association 
between obesity and the dreaded metabolic syndrome, hypertension, diabetes, 
hyperuricemia, dyslipidemia, and sleep apnea indirectly has deleterious effects on kidney 
function.  
3.2.1 Effect of hypertension on kidney function 
Long standing hypertension causes changes in the kidneys’ glomeruli, vasculature, and the 
tubulointerstitium. These changes are broadly referred to as hypertensive nephrosclerosis.  
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Intimal thickening and luminal narrowing of the renal arteries and glomerular arterioles is 
seen. This is thought to be a consequence of a hypertrophic response to chronic 
hypertension causing medial hypertrophy, followed by deposition of plasma protein 
constituents such as inactive C3b in to the damaged vessel wall. Abnormal metabolism of 
nitric oxide is thought to play a major role in this process. This can eventually lead to an 
ischemic state within the kidney. 
The glomeruli may undergo focal global/segmental sclerosis as a consequence of the 
ensuing ischemic injury. This ischemia also causes alterations in antigen expression on the 
surface of the tubular cells, inciting an inflammatory response that leads to chronic 
interstitial nephritis. These alterations cause a decrease in GFR.  
3.2.2 Effect of diabetes on kidney function 
Glomerular hyperfiltration and hypertension is a well studied phenomenon that develops 
early in the course of diabetes. However, elevated glucose levels are known to stimulate 
mesangial cell matrix production. Non-enzymatic glycation of tissue proteins also may 
contribute to the development of diabetic nephropathy. In this process, excess glucose 
combines with free amino acids on circulating or tissue proteins eventually leading to the 
formation of advanced glycation end products (AGEs). These AGEs then crosslink with 
collagen and cause vascular complications. Glomerular permeability is also thought to 
increase via activation of protein kinase C that happens in diabetes.  
Other molecules that have been postulated to have a role in the development  
of nephropathy in diabetes include prorenin (which activates protein kinases, and  
hence mitosis), and other cytokines that cause inflammation and fibrosis. These cytokines 
include vascular endothelial growth factor (VEGF), transforming growth factor-beta  
(TGF-beta) etc. 
3.2.3 Hyperuricemia and kidney function 
Elevated levels of uric acid, or hyperuricemia, that can progress to gout is more prevalent in 
the obese population. It has been proposed that hyperuricemia may contribute to worsening 
of renal function by decreasing renal perfusion. This happens because of arteriolosclerosis  
of the afferent arterioles. It is believed that uric acid stimulates afferent arteriolar  
vascular smooth muscle cell proliferation. Long standing hyperuricemia and gout can 
potentially cause chronic urate nephropathy, and uric acid stones to form in the kidneys or 
the urinary tract.  
3.2.4 Hyperlipidemia and renal function 
It has been shown in animal models that hyperlipidemia can cause mesangial cell 
proliferation by activating LDL receptors present on mesangial cells. This also leads to 
increased production of inflammatory growth factors and reactive oxygen species.  
3.2.5 Metabolic syndrome 
Metabolic syndrome is the dreaded constellation of clinical signs that include increased 
waist circumference, insulin resistance, hypertension, and dyslipidemia. These 
comorbidities act in concert to cause kidney dysfunction through the pathways outlined 
above.  
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4. Obesity and kidney disease: The clinico-pathologic manifestations 
Before clinical kidney disease is apparent in obesity, patients might already have very 
limited renal disease in a few glomeruli, as discussed in section 3.1. Subclinical disease, with 
sclerotic lesions in a few glomeruli (with no overt proteinuria) was demonstrated in a series 
of 95 patients who had renal biopsies while undergoing bariatric surgery for extreme 
obesity. FSGS was observed in approximately 5 percent of extremely obese patients but not 
in any of the non-obese patients. Mesangial and podocyte hypertrophy also occurred more 
frequently in obese patients.  
Early markers of glomerular disease like microalbuminuria and albuminuria have been 
reported in as much as 41% and 4% of the extremely obese patients, respectively. Focal 
segmental glomerulosclerosis (FSGS) and obesity-related glomerulopathy (ORG), 
characterized by glomerular enlargement and mesangial expansion have been described in 
patients with severe obesity, and clinically manifest initially with proteinuria, and in severe 
states can progress to renal failure. Obesity-related glomerulopathy may be reversible with 
weight loss.  
How Obesity Causes Kidney 
Disease 
Direct effects Indirect effects 
Dysregulated production of 
adipokines, e.g., 
angiotensinogen, resistin  
Proinflammatory state 
Glomerular capillary 
hypertension, 
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Hypertension causing 
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nephrosclerosis 
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AGEs 
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afferent arteriosclerosis 
Hyperlipidemia causing 
mesangial cell 
proliferation 
 GFR, CKD, 
ESRD 
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The term "obesity-related glomerulopathy" is sometime used interchangeably with FSGS 
associated with obesity. However, multiple studies have shown that these might be different 
processes pathologically. It is entirely possible that these entities represent a spectrum of 
kidney disease. In 1985, Wesson et al were one of the first ones to report nephrotic range 
heavy proteinuria in patients who had no glomerulosclerosis and no epithelial cell injury or 
foot process fusion on renal biopsy. Later studies reported some of such patients to only 
have mesangial expansion and glomerular capillary loop enlargement leading to 
glomerulomegaly. Classically, ORG is considered to be distinct from idiopathic FSGS, with a 
lower incidence of nephrotic syndrome and a more indolent course. Glomerulomegaly is 
typically more consistent in ORG, as is milder foot process fusion. 
Obese patients with FSGS tend to have elevated glomerular filtration rates and increased 
glomerular size. Serum levels of an adipokine, adiponectin may be seen in the obese. FSGS 
in obese subjects presents with proteinuria that may reach the nephrotic range. Both weight 
loss and ACE inhibitors have been shown to reduce this protein excretion by up to 85 
percent. However, just like the other causes of secondary FSGS, nephrotic syndrome is 
atypical and the presence of edema is uncommon.. Praga et al studied 15 patients with 
obesity associated FSGS with significant proteinuria (mean of 3.1 g/day), and found that 
edema and hypoalbuminemia were not observed in any individual.   
It has been suggested that the difference between obesity-related glomerulonephropathy or 
secondary-FSGS from obesity, and idiopathic FSGS is that only some nephrons leak protein 
in the former, as opposed to global nephron involvement in idiopathic FSGS. This leakage of 
protein then leads to abnormal renal handling of sodium, which subsequently causes 
retention of salt and water. Hence ORG and obesity-related secondary FSGS is not 
associated with edema while the edema in idiopathic FSGS is severe.  
Kambham et al reported in their landmark study that the mean age of patients at the time of 
biopsy diagnosis of ORG was 42.9 years (range 8–71 years). The youngest patients in the 
study group included an 8-year-old girl [height 4.0 ft (121.9 cm), weight 190 lbs (86.4 kg)].  
The patients' weights ranged from 81.8 kg to 186.4 kg. The mean BMI was 41.7 kg/m2 (range 
of 30.9 to 62.7); 38 patients had BMI> 40 kg/m2 and 33 had BMI <40 kg/m2. Their was a 
slight male preponderance with a male-to-female ratio of 44:27 (1.6). The majority of patients 
were Caucasian (75%), followed by African American (21%) and Hispanic (4%). None of 
these patients had renal biopsy findings of diabetic nephropathy. Forty-four patients had a 
prior history of hypertension and eight patients carried a diagnosis of obstructive sleep 
apnea syndrome prior to renal biopsy. 
There are other ways in which obesity can affect renal function. Obesity and weight gain 
during adulthood have been known to increase the risk of kidney stones. In women, obesity 
is an important risk factor for urinary incontinence.   
4.1 Clinical course 
As stated above, weight loss, and drugs like ACE inhibitors can stem the progression of 
kidney disease in obesity and actually reverse the changes (unless most of the glomeruli are 
already fibrosed). Weight loss may result in remission of proteinuria. This was 
demonstrated in a study of 63 patients with biopsy-demonstrated ORG. Patients who 
started the study had a mean protein excretion of 1.48 g/day.  These patients were then 
followed for two years. Protein excretion was reduced from 1.7 to 1 g/24 hours among 29 
patients who successfully lowered their BMI but increased among 9 patients whose BMI 
went up. 
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In patients in whom this does not happen, the disease can progress relentlessly with a 
progressive decrease in GFR. Uremic symptoms can ensue below a GFR of 15 ml/min, and 
eventually, symptoms like failure to thrive, dysgeusia, nausea, vomiting, itching, insomnia, 
hyperkalemia, fluid overload, or acidosis can mandate the initiation of dialysis.  
5. Managing the disease 
Obesity associated kidney disease is a ticking time bomb, and the affected patient stands a 
huge risk of progression to End Stage Renal Disease (ESRD) that mandates dialysis, a 
treatment that is hugely cumbersome and expensive. It is hence imperative that the disease 
be diagnosed and managed aggressively from the outset. It goes without saying that weight 
loss is of utmost importance and can itself cause remission of the disease to a certain extent. 
However, treatment of associated risk factors like hypertension, diabetes or insulin 
resistance, sleep apnea, dyslipidemia is also necessary.  
Medications that block the renin-angiotensin axis in the kidney like the angiotensin 
converting enzyme (ACE) inhibitors, or angiotensin receptor blockers (ARBs) have been 
shown to have a beneficial effect on reducing glomerular hypertension and proteinuria, 
and preventing disease progression. Praga at al demonstrated this in 17 obese patients 
with proteinuria>1 g/day. Their age was 34-70 years; 11 were females and 6 males. Renal 
biopsy was done in five of these patients. This showed focal glomerulosclerosis in 2 cases, 
minimal changes in 2 and mesangial proliferation in 1. Nine patients (group 1) were then 
put on hypocaloric diets and followed for one year. There was a significant correlation 
between body weight loss and decrease in proteinuria. A second group of eight patients 
were started on captopril, an ACE inhibitor (without any dietary changes). BMI in this 
group remained stable but proteinuria showed a dramatic decrease, similar to that in 
group 1. Given the findings of this study, it makes clinical sense to prescribe both body 
weight loss and ACE inhibitor treatment to patients suspected to have obesity related 
kidney disease. 
6. Conclusion  
The World Health Organization considers obesity an international epidemic, stating in 1997 
that “obesity’s impact is so diverse and extreme that it should now be regarded as one of the 
greatest neglected public health problems of our time with an impact on health which may 
well prove to be as great as that of smoking.” Despite scientific evidence to the contrary, the 
effect of obesity on the function of the kidneys is less well-known. There now is a well 
established risk between obesity and the development of kidney disease. The Framingham 
Offspring reported obesity as a major risk factor for the development of kidney disease 
Kidney disease from obesity can progress to End Stage Renal Disease (ESRD), which 
mandates the use of dialysis to keep the patient alive. It is hence a huge risk factor for 
morbidity and mortality. 
Obesity is associated with multiple other conditions that are known to cause compromised 
renal function, including hypertension, diabetes, hyperuricemia, and the metabolic 
syndrome that can independently have a detrimental effect on renal function. However, 
obesity has been found to cause kidney disease and ESRD even after adjustment for these 
factors. The pathogenesis of obesity related kidney disease can be sub-classified in to direct 
and indirect effects. 
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Obesity seems to cause a change in the renal hemodynamics that promotes progressive 
kidney disease. These changes begin early in the course of obesity, even before overt renal 
manifestations of obesity are clinically apparent. One of the keys to unravel obesity’s 
effect on the kidneys is to understand the concept of body fat as an independent 
endocrine organ rather than simply a passive storage depot for triglycerides. A central 
factor in this is the dysregulated production by adipose cells of bioactive substances, 
called “adipokines” that cause systemic effects and directly influence insulin sensitivity 
and vascular injury. This results in hemodynamic and structural changes in the kidney. 
These adipokines include cytokines like leptin, adiponectin, interleukin-6, tumor necrosis 
factor-alpha, resistin, and angiotensinogen. These cytokines then induce a pro-
inflammatory state causing glomerular capillary hypertension and fibrosis in the renal 
parenchyma. Of these adipokines, one of the best understood roles is that of 
angiotensinogen. Increased angiotensinogen kick-starts the RAS and in turn increases the 
downstream effects of this system, namely, fluid retention and increased vascular tone. 
 Elevated levels of angiotensinogen and angiotensin II then lead to efferent arteriolar 
constriction in the glomerulus. This increases the intraglomerular pressure, leading to a 
rise in the GFR. 
Obese patients have been shown to have elevations in both renal plasma flow (RPF) and 
GFR. The augmented RPF suggests a state of renal vasodilatation involving mainly the 
afferent arteriole. The analysis suggests that the high GFR in very obese subjects may be the 
result of an increase in transcapillary hydraulic pressure difference. An abnormal 
transmission of increased arterial pressure to the glomerular capillaries through a dilated 
afferent arteriole could account for the augmentation in this transcapillary pressure. 
Certain pathognomonic changes are seen in the kidney as a result of long standing obesity. 
These changes encompass what is referred to as Obesity Related Glomerulopathy (ORG). 
These include structural changes like hyperplasia of the juxta-glomerular apparatus, 
consistent presence of glomerulomegaly, and foot process fusion. Another histologic feature 
noted in some ORG patients is the presence of focal changes in the form of mild focal 
mesangial sclerosis or mild focal thickening of glomerular/tubular basement membranes. 
These changes are not very dissimilar to changes that are more often associated with the 
presence of diabetic nephropathy.  
The strong association between obesity and other entities like the dreaded metabolic 
syndrome, hypertension, diabetes, hyperuricemia, dyslipidemia, and sleep apnea also 
causes indirect effects on renal structure and function. Long standing hypertension causes 
changes in the kidneys’ glomeruli, vasculature, and the tubulointerstitium. These changes 
are broadly referred to as hypertensive nephrosclerosis.  Intimal thickening and luminal 
narrowing of the renal arteries and glomerular arterioles is seen. The glomeruli may 
undergo focal global/segmental sclerosis as a consequence of the ensuing ischemic injury. 
Glomerular hyperfiltration and hypertension is a well studied phenomenon that develops 
early in the course of diabetes. Elevated glucose levels are known to stimulate mesangial cell 
matrix production. Non-enzymatic glycation of tissue proteins also may contribute to the 
development of diabetic nephropathy. It has been proposed that hyperuricemia may 
contribute to worsening of renal function by decreasing renal perfusion. This happens 
because of arteriolosclerosis of the afferent arterioles. It is believed that uric acid stimulates 
afferent arteriolar vascular smooth muscle cell proliferation. It has been shown in animal 
models that hyperlipidemia can cause mesangial cell proliferation by activating LDL 
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receptors present on mesangial cells. This leads to increased production of inflammatory 
growth factors and reactive oxygen species.  
Before overt clinical kidney disease becomes clinically apparent in obesity, patients may 
start to develop limited renal disease in a few glomeruli. Early markers of glomerular 
disease like microalbuminuria and albuminuria have been reported in as much as 41% and 
4% of the extremely obese patients, respectively. Focal segmental glomerulosclerosis (FSGS) 
and obesity-related glomerulopathy (ORG), as explained above, have been described in 
patients with severe obesity, and manifest initially with proteinuria. These can, in severe 
states, progress to renal failure. However, as is the case with other causes of secondary 
FSGS, nephrotic syndrome is atypical and the presence of edema is uncommon. It has been 
suggested that the difference between obesity-related glomerulonephropathy or secondary-
FSGS from obesity, and idiopathic FSGS is that only some nephrons leak protein in the 
former, as opposed to global nephron involvement in idiopathic FSGS.  
Weight loss, and drugs like ACE inhibitors (eg captopril, lisinopril) or angiotensin receptor 
blockers (like losartan, irbesartan) can stem the progression of kidney disease in obesity, and 
are sometimes able to actually reverse the changes induced by obesity related kidney 
disease. However, this is less likely to happen if most of the glomeruli are already fibrosed. 
In such cases, the disease can progress relentlessly with a progressive decrease in GFR. 
Uremic symptoms can ensue below a GFR of 15 ml/min, and eventually, symptoms like 
failure to thrive, dysgeusia, nausea, vomiting, itching, insomnia, hyperkalemia, fluid 
overload, or acidosis can mandate the initiation of dialysis. It thus makes clinical sense to 
prescribe both weight loss and ACE inhibitor/angiotensin receptor blocker treatment to 
patients suspected of having obesity related kidney disease.  
7. Methods 
We searched PubMed for English, German, French, and Spanish language references 
published as of June 2011, using combinations of the following terms: “obesity”, “kidney 
disease”, “glomerulopathy”, “FSGS”, “gastric bypass”, “diabetes mellitus”, “dyslipidemia”, 
“hypertension”, “metabolic syndrome”, “metabolic effects”, “renal effects”, “nutrition”, 
“epidemiology”. The bibliographies of the articles thus obtained, as well as those of relevant 
review articles were also reviewed for inclusion of publications. 
8. References 
Bellomo G., et al. (2010). Association of uric acid with change in kidney function in healthy 
normotensive individuals. Am J Kidney Dis, Vol. 56, No. 2, (2010 Aug), pp. 264- 
272    
Caballero, B. (2007). The global epidemic of obesity: an overview. Epidemiol Rev, Vol. 29, pp 
1-5. (Epub 2007 Jun 13) 
Chagnac A., et al. (2000). Glomerular hemodynamics in severe obesity. Am J Physiol Renal 
Physiol, Vol. 278, No. 5, (2000 May), pp. 817-822 
Choi, H., et al. (2005). Obesity, weight change, hypertension, diuretic use, and risk of gout in 
men: the health professionals follow-up study. Arch Intern Med, Vol. 165, No. 7, 
(2005 April), pp. 742-748 
www.intechopen.com
 
The Obesity Epidemic and Kidney Disease: A Literature Review 
 
55 
Flegal, K, et al. (2010). Prevalence and trends in obesity among US adults, 1999-2008. JAMA, 
Vol. 303, No. 3, (2010 Jan), pp. 235-241 
Fox, C., et al. (2004). Predictors of new-onset kidney disease in a community-based 
population. JAMA, Vol. 291, No. 7, (2004 Feb), pp. 844-850 
Gröne E., & Gröne H. (2008). Does hyperlipidemia injure the kidney? Nat Clin Pract Nephrol, 
Vol. 4, No. 8, (2008 Aug), pp. 424-425 
Harris, R., et al. (1991). Global glomerular sclerosis and glomerular arteriolar hyalinosis  
in insulin dependent diabetes. Kidney Int, Vol. 40, No. 1, (1991 July), pp. 107- 
114 
Hsu, C., et al. (2006). Body mass index and risk for end-stage renal disease. Ann Intern Med, 
Vol. 144, No. 1, (2006 Jan), pp. 21-28    
Hsu, C., et al. (2009). Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern 
Med, Vol. 169, No. 4, (2009 Feb), pp. 342-350 
Hutley, L., Prins, J. (2005). Fat as an endocrine organ: relationship to the metabolic 
syndrome. Am J Med Sci, Vol. 330, No. 6, (2005 Dec), pp. 280-289  
Kambham, N., et al. (2001). Obesity-related glomerulopathy: an emerging epidemic. Kidney 
Int, Vol. 59, No. 4, (2001 Apr), pp. 1498-1509 
Karlsson, C., et al. (1998) Human adipose tissue expresses angiotensinogen and enzymes 
required for its conversion to angiotensin II. J Clin Endocrinol Metab, Vol. 83,  No. 11, 
(1998 Nov), pp. 3925–3929 
Kramer, H., et al. (2005). Obesity and prevalent and incident CKD: the Hypertension 
Detection and Follow-Up Program. Am J Kidney Dis, Vol. 46, No. 4, (2005 Oct), pp. 
587-594 
Malik, F.,  et al. (1997). Renin-angiotensin system: genes to bedside. Am Heart J, Vol. 134, No. 
3, (1997 Sep), pp. 514–526 
Morales E., et al. (2003). Beneficial effects of weight loss in overweight patients with chronic 
proteinuric nephropathies. Am J Kidney Dis, Vol. 41, No. 2, (2003 Feb), pp. 319- 
327 
Praga M., et al. (2001). Clinical features and long-term outcome of obesity-associated focal 
segmental glomerulosclerosis. Nephrol Dial Transplant, Vol. 16, No. 9, (2001 Sep), pp. 
1790-1798 
Praga M., et al. (1995). Effects of body-weight loss and captopril treatment on proteinuria 
associated with obesity. Nephron, Vol. 70, No. 1, (1995), pp. 35-41 
Schieffer, B., et al. (2004). Comparative effects of AT1-antagonism and angiotensin-
converting enzyme inhibition on markers of inflammation and platelet aggregation 
in patients with coronary artery disease. J Am Coll Cardiol, Vol. 44, No. 2, (2004 
July), pp. 362–368 
Serra, A., et al. (2008). Renal injury in the extremely obese patients with normal renal 
function. Kidney Int, Vol. 73, No. 8, (2008 Apr), pp. 947-955 
Shen W., et al. (2010). Obesity-related glomerulopathy: body mass index and proteinuria. 
Clin J Am Soc Nephrol, Vol. 5, No. 8, (2010 Aug), pp. 1401-1409 
Taylor E., et al. (2005). Obesity, weight gain, and the risk of kidney stones. JAMA, Vol 293, 
No. 4, (2005 Jan), pp. 455-462 
The world health report 2002 - Reducing Risks, Promoting Healthy Life, Geneva, 
Switzerland, 2002 
www.intechopen.com
 
Diseases of Renal Parenchyma 
 
56
Wesson D., et al. (1985). Massive obesity and nephrotic proteinuria with a normal renal 
biopsy. Nephron, Vol. 40, No. 2, (1985), pp. 235-237 
www.intechopen.com
Diseases of Renal Parenchyma
Edited by Prof. Manisha Sahay
ISBN 978-953-51-0245-8
Hard cover, 304 pages
Publisher InTech
Published online 16, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Clinical nephrology is an evolving speciality in which the amount of information is growing daily. This book
gives quick access to some important clinical conditions encountered in nephrology including the diseases of
glomeruli, tubules and interstitium. It presents the latest information on pathophysiology, diagnosis and
management of important diseases of renal parenchyma. The information is presented in a very user friendly
and accessible manner while the treatment algorithms enable the reader to quickly access expert advice on
arriving at the most appropriate treatment regimen. The book discusses the renal involvement in various
systemic diseases including diabetes and autoimmune diseases. Diabetic nephropathy is fast becoming the
commonest cause of end stage renal disease all over the globe and is discussed in this book. The editors
believe that this book will be a valuable addition to the reader's library.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Veeraish Chauhan, Megha Vaid, Nishtha Chauhan and Akhil Parashar (2012). The Obesity Epidemic and
Kidney Disease: A Literature Review, Diseases of Renal Parenchyma, Prof. Manisha Sahay (Ed.), ISBN: 978-
953-51-0245-8, InTech, Available from: http://www.intechopen.com/books/diseases-of-renal-parenchyma/the-
obesity-epidemic-and-kidney-disease-a-literature-review
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
